Browsing Tag
CD19
2 posts
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.
AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy
AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details.